Weekly Top News – Breast Cancer– January 6, 2020

Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZenecaEnhertu now available in U.S. for HER2 positive unresectable or metastatic breast cancer following two or more prior anti-HER2-based regimens (Businesswire) - Jan 6, 2020 - "Daiichi Sankyo Company, Limited...announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2 directed antibody drug conjugate, is now available by prescription in the U.S....ENHERTU was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on December 20, 2019 for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting."Tuoyi (toripalimab) / Shanghai Junshi BioscienceJunshi Bio and CSPC Pharma disengage from Tuoyi/paclitaxel deal (GBI Health) - Dec 31, 2019 - "China-based CSPC Pharmaceutical Group Ltd (1093.HK) and Shanghai Junshi Biosciences Co Ltd have agreed to terminate a deal struck in June 2018 in relation to programmed death-1 (PD-1) monoclonal antibody (mAb) Tuoyi (toripalimab) combined with paclitaxel in treating breast cancer. The firms cite a 'potential conflict of interests in terms of CSPC Pharma’s PD-1 mAb development' as the reason for the cancellation...Per the termination agreement, the milestone payments and RMB 3.68 million (527,000) in clinical development expenses paid to Junshi Bio will not be refunded, and no further milestone payments will be made."Faslodex (fulvestrant) / AstraZeneca; AZD9833 / AstraZenecaSERENA-2: A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer (clinicaltrials.gov) - Jan 2, 2020 - P2; N=288; Not yet recruiting; Sponsor: AstraZenecaImfinzi (durvalumab) / AstraZeneca, BMSImfinzi sales projection: $4.8B in 2025 (Cowen & Co) - Jan 3, 2020 - A subscription to Thomson ONE is required to gain full access to report 68527170; Page no: 7; REPORT TITLE: "Portfolio manager's weekly - December 20, 2019”; AUTHOR: Cowen Research, et al; DATE: 12/20/2019